Thrombo-embolic complications related to hormone therapy of breast cancer - a case report
Journal Title: OncoReview - Year 2013, Vol 3, Issue 1
Abstract
69-year old female with breast cancer treated with surgery (total mastectomy) and cheamo- and radiotherapy, with cancer in right breast operated last year, with further hormone therapy with tamoxifen, suffered from low risk pulmonary embolism. She was treated with streptokinase which was complicated by intracerebral bleeding. The patient was referred to the neurosurgeon and conservative treatment was ordered. Than she was transferred to Department of Pulmonary Circulation and Thromboembolic Diseases, ECZ Otwock where vena cava filter was implanted as prevention of recurrence pulmonary embolism. Progression of deep venous thrombosis associated with thrombosis in vena cava filter and the ”resistance” to treatment using enoxaparin was observed. The inclusion of unfractionated heparin in continuous intravenous infusion, withdrawal of tamoxifen and intensification diuretic therapy has improved patient’s status and allowed discharge from hospital.
Authors and Affiliations
Szymon Darocha, Sebastian Szmit, Łukasz Kownacki, Marcin Kurzyna
Keywords
Related Articles
- EP ID EP53208
- DOI -
- Views 188
- Downloads 0
Quality of life in oncology and quality of life in course of molecularly targeted therapy in patients diagnosed with metastatic renal-cell carcinoma
Introduction of molecularly targeted agents into clinical practice has led to marked progress in pharmacotherapy of advanced renal cell carcinoma. There have been six drugs of the therapeutic class registered to date. Fu...
Cardiotoxicity of radiotherapy in breast cancer patients
Sequential oncological therapy and delays in oncological diagnostics and treatment
One of the causes behind the low recovery rate among oncological patients is late diagnosis and delayed treatment. To a large extent it stems from the limited access to standard diagnostic methods, and from the extended...
Czy antagoniści receptorów angiotensynowych AT1 (sartany) mogą zwiększać ryzyko wystąpienia choroby nowotworowej? Komentarz kardiologa i hipertensjologa
Progress in treatment of multiple myelomain year 2012